Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiation Oncology | 12 | 2022 | 29 | 3.490 |
Why?
|
| Racism | 4 | 2023 | 50 | 1.470 |
Why?
|
| Breast Neoplasms | 7 | 2024 | 2602 | 1.110 |
Why?
|
| Mammography | 3 | 2024 | 122 | 1.030 |
Why?
|
| Minority Groups | 6 | 2018 | 259 | 1.030 |
Why?
|
| Brachytherapy | 3 | 2025 | 85 | 0.990 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2018 | 107 | 0.950 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 355 | 0.800 |
Why?
|
| Medicine | 2 | 2022 | 99 | 0.740 |
Why?
|
| Health Equity | 1 | 2023 | 77 | 0.720 |
Why?
|
| Diagnostic Imaging | 2 | 2014 | 304 | 0.690 |
Why?
|
| Physicians | 5 | 2020 | 636 | 0.670 |
Why?
|
| Sex Distribution | 4 | 2019 | 319 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1268 | 0.650 |
Why?
|
| Education, Medical, Graduate | 4 | 2020 | 551 | 0.630 |
Why?
|
| Mass Screening | 4 | 2024 | 811 | 0.620 |
Why?
|
| Prostate-Specific Antigen | 2 | 2021 | 222 | 0.610 |
Why?
|
| Personnel Selection | 2 | 2018 | 79 | 0.610 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 108 | 0.610 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2025 | 266 | 0.600 |
Why?
|
| Sexism | 3 | 2022 | 43 | 0.590 |
Why?
|
| Sexual Health | 1 | 2018 | 19 | 0.570 |
Why?
|
| Cultural Diversity | 5 | 2018 | 81 | 0.570 |
Why?
|
| Health Communication | 1 | 2018 | 30 | 0.560 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 43 | 0.560 |
Why?
|
| Chemoradiotherapy | 5 | 2025 | 123 | 0.540 |
Why?
|
| Radiotherapy Dosage | 4 | 2024 | 217 | 0.540 |
Why?
|
| Organs at Risk | 1 | 2018 | 48 | 0.540 |
Why?
|
| Prostatic Neoplasms | 3 | 2023 | 1408 | 0.530 |
Why?
|
| Faculty, Medical | 6 | 2020 | 281 | 0.530 |
Why?
|
| Lung Neoplasms | 2 | 2024 | 1547 | 0.520 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 173 | 0.510 |
Why?
|
| Survivors | 1 | 2018 | 345 | 0.480 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2024 | 260 | 0.460 |
Why?
|
| Mastectomy | 1 | 2015 | 74 | 0.460 |
Why?
|
| Vagina | 1 | 2016 | 207 | 0.410 |
Why?
|
| Health Personnel | 1 | 2018 | 547 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 1 | 2015 | 402 | 0.390 |
Why?
|
| Sex Ratio | 1 | 2012 | 12 | 0.380 |
Why?
|
| United States | 19 | 2024 | 11883 | 0.370 |
Why?
|
| Female | 30 | 2025 | 70425 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2023 | 3752 | 0.360 |
Why?
|
| Humans | 43 | 2025 | 130555 | 0.350 |
Why?
|
| Head and Neck Neoplasms | 4 | 2020 | 635 | 0.350 |
Why?
|
| Neoplasms | 2 | 2023 | 2985 | 0.340 |
Why?
|
| Biomarkers, Tumor | 1 | 2019 | 1586 | 0.340 |
Why?
|
| Veterans | 4 | 2022 | 1753 | 0.320 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 2101 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 747 | 0.310 |
Why?
|
| Radiation Oncologists | 2 | 2020 | 4 | 0.300 |
Why?
|
| Aged | 13 | 2025 | 20899 | 0.290 |
Why?
|
| Administrative Personnel | 2 | 2019 | 26 | 0.280 |
Why?
|
| Internship and Residency | 4 | 2022 | 1218 | 0.270 |
Why?
|
| Middle Aged | 12 | 2025 | 28415 | 0.250 |
Why?
|
| Male | 22 | 2024 | 64534 | 0.250 |
Why?
|
| Radiation Injuries | 2 | 2025 | 141 | 0.240 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2024 | 125 | 0.240 |
Why?
|
| Physicians, Women | 2 | 2017 | 54 | 0.240 |
Why?
|
| Hydronephrosis | 1 | 2025 | 34 | 0.220 |
Why?
|
| Positron-Emission Tomography | 2 | 2024 | 290 | 0.220 |
Why?
|
| Students, Medical | 2 | 2023 | 352 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2024 | 97 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 36 | 0.200 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 416 | 0.190 |
Why?
|
| Public Health Surveillance | 2 | 2019 | 42 | 0.190 |
Why?
|
| Sexual Harassment | 1 | 2022 | 19 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2024 | 12865 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 4867 | 0.170 |
Why?
|
| Abortion, Induced | 1 | 2022 | 89 | 0.170 |
Why?
|
| Breast | 1 | 2022 | 213 | 0.170 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 78 | 0.170 |
Why?
|
| Pharyngeal Muscles | 1 | 2020 | 10 | 0.170 |
Why?
|
| Blood Volume | 1 | 2020 | 73 | 0.160 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2021 | 104 | 0.150 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 132 | 0.140 |
Why?
|
| Schools, Medical | 1 | 2019 | 116 | 0.140 |
Why?
|
| Computer Simulation | 1 | 2021 | 671 | 0.140 |
Why?
|
| Kidney | 1 | 2025 | 1280 | 0.140 |
Why?
|
| Orchiectomy | 1 | 2018 | 46 | 0.140 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 697 | 0.140 |
Why?
|
| Prostatectomy | 1 | 2019 | 304 | 0.140 |
Why?
|
| Colon, Sigmoid | 1 | 2018 | 11 | 0.140 |
Why?
|
| Heart | 1 | 2022 | 660 | 0.140 |
Why?
|
| Health Expenditures | 1 | 2019 | 134 | 0.140 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2018 | 75 | 0.140 |
Why?
|
| Sex Factors | 2 | 2019 | 1340 | 0.140 |
Why?
|
| Employee Performance Appraisal | 1 | 2017 | 12 | 0.130 |
Why?
|
| Achievement | 1 | 2017 | 32 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2019 | 293 | 0.130 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 683 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2018 | 173 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2023 | 558 | 0.130 |
Why?
|
| Rectum | 1 | 2018 | 101 | 0.130 |
Why?
|
| Radiation Dosage | 1 | 2018 | 132 | 0.130 |
Why?
|
| Models, Theoretical | 1 | 2019 | 360 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 320 | 0.130 |
Why?
|
| Patient Preference | 1 | 2018 | 151 | 0.120 |
Why?
|
| Women, Working | 1 | 2016 | 8 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2019 | 388 | 0.120 |
Why?
|
| Hematology | 1 | 2017 | 42 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2019 | 1210 | 0.120 |
Why?
|
| Radiology, Interventional | 1 | 2016 | 30 | 0.120 |
Why?
|
| Urinary Bladder | 1 | 2018 | 219 | 0.120 |
Why?
|
| Medical Oncology | 2 | 2017 | 242 | 0.120 |
Why?
|
| Specialization | 1 | 2016 | 75 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 3 | 2022 | 237 | 0.120 |
Why?
|
| Quality of Life | 2 | 2023 | 2074 | 0.120 |
Why?
|
| Time Factors | 4 | 2020 | 6215 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 155 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 439 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 387 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 2063 | 0.100 |
Why?
|
| Cohort Studies | 2 | 2022 | 5049 | 0.100 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 903 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 6800 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 713 | 0.090 |
Why?
|
| Physics | 2 | 2022 | 12 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2024 | 6438 | 0.090 |
Why?
|
| Incidence | 3 | 2025 | 3320 | 0.090 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2011 | 18 | 0.090 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 1280 | 0.090 |
Why?
|
| Patient Selection | 1 | 2015 | 725 | 0.090 |
Why?
|
| Nose Neoplasms | 1 | 2011 | 31 | 0.090 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 4034 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 101 | 0.080 |
Why?
|
| Registries | 2 | 2016 | 1614 | 0.080 |
Why?
|
| Consensus | 2 | 2022 | 517 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5164 | 0.080 |
Why?
|
| Adult | 6 | 2025 | 31157 | 0.070 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2023 | 221 | 0.070 |
Why?
|
| Disease Progression | 1 | 2015 | 2193 | 0.070 |
Why?
|
| Mentors | 2 | 2022 | 169 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2023 | 706 | 0.060 |
Why?
|
| Linear Models | 2 | 2020 | 686 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2015 | 3678 | 0.060 |
Why?
|
| Career Choice | 2 | 2018 | 167 | 0.060 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2025 | 16 | 0.060 |
Why?
|
| Age Factors | 2 | 2024 | 2830 | 0.060 |
Why?
|
| Medical Overuse | 1 | 2024 | 23 | 0.050 |
Why?
|
| Carboplatin | 1 | 2024 | 80 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2024 | 142 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2024 | 131 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 160 | 0.050 |
Why?
|
| Social Identification | 1 | 2023 | 22 | 0.050 |
Why?
|
| Unemployment | 1 | 2023 | 23 | 0.050 |
Why?
|
| Cisplatin | 1 | 2025 | 274 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 33 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2024 | 179 | 0.050 |
Why?
|
| Developed Countries | 1 | 2022 | 43 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2024 | 484 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2024 | 292 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2022 | 130 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 73 | 0.040 |
Why?
|
| Cause of Death | 1 | 2023 | 502 | 0.040 |
Why?
|
| Risk Factors | 1 | 2015 | 10967 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2024 | 385 | 0.040 |
Why?
|
| Androgen Antagonists | 1 | 2021 | 104 | 0.040 |
Why?
|
| Deglutition | 1 | 2020 | 54 | 0.040 |
Why?
|
| Nitriles | 1 | 2021 | 162 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 77 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 303 | 0.040 |
Why?
|
| Image Enhancement | 1 | 2020 | 160 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2024 | 390 | 0.040 |
Why?
|
| SEER Program | 1 | 2020 | 213 | 0.040 |
Why?
|
| Budgets | 1 | 2019 | 15 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2019 | 142 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1447 | 0.040 |
Why?
|
| Employment | 1 | 2019 | 71 | 0.040 |
Why?
|
| Efficiency | 1 | 2019 | 74 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 981 | 0.030 |
Why?
|
| Enteral Nutrition | 1 | 2020 | 286 | 0.030 |
Why?
|
| Spouses | 1 | 2019 | 71 | 0.030 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2022 | 713 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 564 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1288 | 0.030 |
Why?
|
| Contrast Media | 1 | 2020 | 474 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1332 | 0.030 |
Why?
|
| Self Report | 1 | 2019 | 551 | 0.030 |
Why?
|
| Leadership | 1 | 2019 | 245 | 0.030 |
Why?
|
| Forecasting | 1 | 2018 | 350 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 903 | 0.030 |
Why?
|
| Lung | 1 | 2024 | 1537 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2018 | 452 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1804 | 0.030 |
Why?
|
| Education | 1 | 2015 | 112 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2025 | 17557 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2011 | 4 | 0.020 |
Why?
|
| Radiodermatitis | 1 | 2011 | 9 | 0.020 |
Why?
|
| Stomatitis | 1 | 2011 | 14 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2011 | 45 | 0.020 |
Why?
|
| Nasal Cavity | 1 | 2011 | 56 | 0.020 |
Why?
|
| Biomarkers | 1 | 2020 | 3386 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2014 | 323 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2011 | 347 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7403 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 10015 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 20774 | 0.010 |
Why?
|
| Child | 1 | 2011 | 26175 | 0.010 |
Why?
|